Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).

Garber, A J; Wahlen, J; Wahl, T; Bressler, P; Braceras, R; Allen, E; Jain, R
Diabetes, obesity & metabolism; 2006 Jan;8(1):58-66. PMID: 16367883
Baylor College of Medicine, Houston, TX 77030, USA.


This observational study in patients with type 2 diabetes failing oral agent therapy with or without basal insulin was conducted to assess whether addition and self-titration of biphasic insulin aspart 70/30 (BIAsp 30) could achieve American Association of Clinical Endocrinologists (AACE)/International Diabetes Federation (IDF) and American Diabetes Association (ADA) glycemic targets (HbA(1c)< or =6.5 and <7%).